WO2005058287A3 - Transdermal delivery system of hormones without penetration enhancers - Google Patents

Transdermal delivery system of hormones without penetration enhancers Download PDF

Info

Publication number
WO2005058287A3
WO2005058287A3 PCT/IB2004/052752 IB2004052752W WO2005058287A3 WO 2005058287 A3 WO2005058287 A3 WO 2005058287A3 IB 2004052752 W IB2004052752 W IB 2004052752W WO 2005058287 A3 WO2005058287 A3 WO 2005058287A3
Authority
WO
WIPO (PCT)
Prior art keywords
hormones
patch
penetration enhancers
delivery system
transdermal delivery
Prior art date
Application number
PCT/IB2004/052752
Other languages
French (fr)
Other versions
WO2005058287A2 (en
Inventor
Stefan Bracht
Michael Dittgen
Petra Huber
Thomas Langguth
Dirk Schenk
Original Assignee
Stefan Bracht
Michael Dittgen
Petra Huber
Thomas Langguth
Dirk Schenk
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US52871803P priority Critical
Priority to EP03078881 priority
Priority to US60/528,718 priority
Priority to EP03078881.4 priority
Application filed by Stefan Bracht, Michael Dittgen, Petra Huber, Thomas Langguth, Dirk Schenk, Schering Ag filed Critical Stefan Bracht
Publication of WO2005058287A2 publication Critical patent/WO2005058287A2/en
Publication of WO2005058287A3 publication Critical patent/WO2005058287A3/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2005058287(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins

Abstract

The present invention relates to a patch comprising a drug-containing layer with low content of hormones, such as gestodene, and optionally an estrogen (e.g. ethinyl estradiol). Upon administering the patch to a woman, plasma levels of at least 1.0 ng/ml of Gestodene is achieved at steady state conditions without the need of incorporating penetration enhancers or permeation enhancers in the drug-containing layer. Satisfactorily plasma levels of the hormones is also achieved throughout a period of at least 1 week, making the patch applicable for being used in female contraception with the concept of administering the patch ones weekly.
PCT/IB2004/052752 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers WO2005058287A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US52871803P true 2003-12-12 2003-12-12
EP03078881 2003-12-12
US60/528,718 2003-12-12
EP03078881.4 2003-12-12

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
CA2549916A CA2549916C (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers
BRPI0417530-1A BRPI0417530B1 (en) 2003-12-12 2004-12-10 Composition for transdermal release of hormones without the need for penetration enhancers, transdermal therapeutic system, and kit
KR1020067013923A KR101168449B1 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers
MXPA06006682A MXPA06006682A (en) 2003-12-12 2004-12-10 Transdermal delivery of hormones without the need of penetration enhancers.
JP2006543709A JP4965263B2 (en) 2003-12-12 2004-12-10 Transdermal delivery of hormones without the need for penetration enhancers
NZ548091A NZ548091A (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers
AU2004298930A AU2004298930B2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers
EA200601089A EA011160B1 (en) 2003-12-12 2004-12-10 A composition for transdermal delivery of hormones without penetration enhancers and its use
CN2004800413210A CN1913878B (en) 2003-12-12 2004-12-10 Transdermal delivery of hormones without the need of penetration enhancers
IL176112A IL176112A (en) 2003-12-12 2006-06-05 Composition for transdermal delivery containing gestodene and a carrier, a transdermal therapeutic system comprising gestodene and a kit
NO20062594A NO341989B1 (en) 2003-12-12 2006-06-06 Transdermal administration of hormones without the need for penetrasjonsenhancere.
ZA2006/05713A ZA200605713B (en) 2003-12-12 2006-07-11 Transdermal delivery system of hormones without penetration enhancers
CU20100143A CU23868B1 (en) 2003-12-12 2010-07-05 Hormones transdermal delivery do not require penetration enhancers

Publications (2)

Publication Number Publication Date
WO2005058287A2 WO2005058287A2 (en) 2005-06-30
WO2005058287A3 true WO2005058287A3 (en) 2006-03-02

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Country Status (15)

Country Link
JP (1) JP4965263B2 (en)
KR (1) KR101168449B1 (en)
CN (1) CN1913878B (en)
AU (1) AU2004298930B2 (en)
BR (1) BRPI0417530B1 (en)
CA (1) CA2549916C (en)
CU (1) CU23868B1 (en)
EA (1) EA011160B1 (en)
EC (1) ECSP066694A (en)
IL (1) IL176112A (en)
MX (1) MXPA06006682A (en)
NO (1) NO341989B1 (en)
NZ (1) NZ548091A (en)
WO (1) WO2005058287A2 (en)
ZA (1) ZA200605713B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073696A1 (en) 2003-02-21 2004-09-02 Schering Ag Uv stable transdermal therapeutic plaster
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
FR2900048B1 (en) * 2006-04-21 2012-11-16 Oreal Compositions comprising a diphenyl-methane hydroxylated derivative
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
WO2012031999A2 (en) 2010-09-06 2012-03-15 Bayer Pharma Aktiengesellschaft Low-dose transdermal patches with high drug release
DE102010040299A1 (en) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
EP2806862A2 (en) * 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992007590A1 (en) * 1990-10-29 1992-05-14 Alza Corporation Transdermal contraceptive formulations, methods and devices
EP0573133A1 (en) * 1988-10-27 1993-12-08 Schering Aktiengesellschaft Means for transdermal application of Gestoden
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
US5858394A (en) * 1993-08-26 1999-01-12 Schering Aktiengesellschaft Agent for transdermal administration that contains gestodene esters
US5904931A (en) * 1994-02-18 1999-05-18 Schering Aktiengesellschaft Transdermal therapeutic systems that contain sex steroids and dimethyl isosorbide
DE19906152A1 (en) * 1999-02-10 2000-08-17 Jenapharm Gmbh Active ingredient-containing laminates for transdermal
WO2002034200A2 (en) * 2000-10-27 2002-05-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic systems comprising photosensitive active substances
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970706805A (en) * 1994-11-18 1997-12-01 나까토미 히로타카 Transdermal patch (percutaneously absorbable patch)
JP4346696B2 (en) * 1996-05-28 2009-10-21 久光製薬株式会社 Transdermal therapeutic device
JP4167750B2 (en) * 1997-04-16 2008-10-22 久光製薬株式会社 Transdermal absorption base and percutaneous absorption preparation containing the base
JP4399044B2 (en) * 1998-10-14 2010-01-13 久光製薬株式会社 Absorption enhancer and transdermal absorption preparation comprising the absorption enhancer
WO2001001990A1 (en) * 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0573133A1 (en) * 1988-10-27 1993-12-08 Schering Aktiengesellschaft Means for transdermal application of Gestoden
WO1992007590A1 (en) * 1990-10-29 1992-05-14 Alza Corporation Transdermal contraceptive formulations, methods and devices
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
US5858394A (en) * 1993-08-26 1999-01-12 Schering Aktiengesellschaft Agent for transdermal administration that contains gestodene esters
US5904931A (en) * 1994-02-18 1999-05-18 Schering Aktiengesellschaft Transdermal therapeutic systems that contain sex steroids and dimethyl isosorbide
DE19906152A1 (en) * 1999-02-10 2000-08-17 Jenapharm Gmbh Active ingredient-containing laminates for transdermal
WO2002034200A2 (en) * 2000-10-27 2002-05-02 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic systems comprising photosensitive active substances
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
MXPA06006682A (en) 2006-08-11
CN1913878B (en) 2010-05-26
BRPI0417530A (en) 2007-03-13
IL176112A (en) 2011-02-28
NZ548091A (en) 2009-12-24
CN1913878A (en) 2007-02-14
KR20060128910A (en) 2006-12-14
CU20100143A7 (en) 2011-10-31
CA2549916A1 (en) 2005-06-30
KR101168449B1 (en) 2012-07-25
NO20062594L (en) 2006-07-10
AU2004298930A1 (en) 2005-06-30
EA011160B1 (en) 2009-02-27
WO2005058287A2 (en) 2005-06-30
NO341989B1 (en) 2018-03-12
JP2007513938A (en) 2007-05-31
IL176112D0 (en) 2006-10-05
CU23868B1 (en) 2013-03-27
AU2004298930B2 (en) 2009-11-26
JP4965263B2 (en) 2012-07-04
ZA200605713B (en) 2008-01-08
ECSP066694A (en) 2006-10-31
BRPI0417530B1 (en) 2018-01-23
EA200601089A1 (en) 2006-12-29
CA2549916C (en) 2013-09-17

Similar Documents

Publication Publication Date Title
CA1316106C (en) Skin permeation enhancer compositions using glycerol monolaurate
EP2305195B1 (en) Drug Delivery Compositions for Improved Stability of Steroids
EP1323431B1 (en) Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
FI114782B (en) Method for producing a patch in the form of a laminate
JP3068187B2 (en) Sub-saturated transdermal drug delivery device for providing a drug flow rate was enhanced
US5314694A (en) Transdermal formulations, methods and devices
AU659457B2 (en) Transdermal fertility control system and process
US5079008A (en) Transdermal monolith systems
US6835392B2 (en) Dual enhancer composition for topical and transdermal drug delivery
JP3534775B2 (en) Transdermal patches and methods for administering 17-deacetylnorgestimate alone or in combination with estrogens
CA2088778C (en) Transdermal contraceptive formulations, methods and devices
EP0721348B1 (en) Monoglyceride/lactate ester permeation enhancer
CN1107522C (en) Skin permeation enhancer compsns. using acyl lactylates
KR100212961B1 (en) Trasdermal drug delivery system
KR950015061B1 (en) Transdermal therapeutic system containing buprenorphine as a active component
DE60118395D1 (en) Pharmaceutical compositions with delayed release for the parenteral application of hydrophilic active substances
DE60018797T2 (en) Hydroxide releasing compounds to improve skin permeability
ES2249763T5 (en) System of transdermic administration of powerful farmaco de flujo bajo.
DE69434491T3 (en) Skin taste contains testosterone and, where appropriate, estrogen
US5198223A (en) Transdermal formulations, methods and devices
US4865848A (en) Skin permeation enhancer compositions using sucrose esters
US4568343A (en) Skin permeation enhancer compositions
CA2017442A1 (en) Transdermal therapeutic composition
WO1991015241A1 (en) Percutaneously absorbable composition of narcotic and nonnarcotic analgesics
WO1987007138A1 (en) Transdermal absorption dosage unit for estradiol and other estrogenic steroids and process for administration

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 176112

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 3279/DELNP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2549916

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006543709

Country of ref document: JP

Ref document number: 12006501154

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: PA/a/2006/006682

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004298930

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: CR2006-008465

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 548091

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 06064000

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 200601089

Country of ref document: EA

ENP Entry into the national phase in:

Ref document number: 2004298930

Country of ref document: AU

Date of ref document: 20041210

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004298930

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/05713

Country of ref document: ZA

Ref document number: 1020067013923

Country of ref document: KR

Ref document number: 200605713

Country of ref document: ZA

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 200480041321.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020067013923

Country of ref document: KR

122 Ep: pct application non-entry in european phase
ENP Entry into the national phase in:

Ref document number: PI0417530

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: D2010143

Country of ref document: CU